Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Lombardi Comprehensive Cancer Center, Georgetown University Hospital
mi
from
Washington,
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Lombardi Comprehensive Cancer Center, Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
University of Florida COllege of Medicine/Shands Cancer Center
mi
from
Gainesville, FL
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
University of Florida COllege of Medicine/Shands Cancer Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
NYU Clinical Trials Office, New York University Cancer Institute
mi
from
New York, NY
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
NYU Clinical Trials Office, New York University Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
La Jolla, CA
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Whittier, CA
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Miami, FL
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Wichita, KA
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Billings, MT
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Farmington, NM
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Farmington, NM
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Bronx, NY
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Memphis, TN
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Galveston, TX
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Houston, TX
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated:  11/5/2015
Clinical Research Facility
mi
from
Temple, TX
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer
Status: Enrolling
Updated: 11/5/2015
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Cedars Sinai Medical Center Cedars Sinai Medical Ctr. (SC)
mi
from
Los Angeles, CA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Cedars Sinai Medical Center Cedars Sinai Medical Ctr. (SC)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Stanford University Medical Center Cancer Clinical Trials Office
mi
from
Stanford, CA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Stanford University Medical Center Cancer Clinical Trials Office
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Florida Cancer Specialists DeptofFloridaCancerSpecialists
mi
from
Fort Myers, FL
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Florida Cancer Specialists DeptofFloridaCancerSpecialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Straub Clinic & Hospital Straub
mi
from
Honolulu, HI
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Straub Clinic & Hospital Straub
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
University of Kansas Cancer Center Univ of KS
mi
from
Kansas City, KA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
University of Kansas Cancer Center Univ of KS
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
University of Maryland Medical Center UMMC
mi
from
Baltimore, MD
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
University of Maryland Medical Center UMMC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
University of Minnesota Medical Center - Fairview Univ of MN
mi
from
Minneapolis, MN
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
University of Minnesota Medical Center - Fairview Univ of MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
mi
from
Las Vegas, NV
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
CINJ at Cooper University Hospital Cooper
mi
from
Voorhees, NJ
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
CINJ at Cooper University Hospital Cooper
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
SUNY - Upstate Medical University Div. of Hematology-Oncology
mi
from
Syracuse, NY
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
SUNY - Upstate Medical University Div. of Hematology-Oncology
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
mi
from
Troy, NY
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC
mi
from
Troy, NY
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Willamette Valley Clinical Studies Williamette Valley Cancer
mi
from
Eugene, OR
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
St. Luke's Hospital and Health Network St Luke's
mi
from
Bethlehem, PA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
St. Luke's Hospital and Health Network St Luke's
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Cancer Centers of the Carolinas CC of C -Eastside
mi
from
Greenville, SC
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Cancer Centers of the Carolinas CC of C -Eastside
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
The West Clinic, PC
mi
from
Memphis, TN
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Vanderbilt University Medical Center SC
mi
from
Nashville, TN
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Vanderbilt University Medical Center SC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Texas Oncology, P.A. Texas Oncology - Houston
mi
from
Dallas, TX
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Texas Oncology, P.A. Texas Oncology - Houston
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Texas Oncology, P.A. Texas Onc - Austin
mi
from
Dallas, TX
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Texas Oncology, P.A. Texas Onc - Austin
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
University of Texas Southwestern Medical Center UTSW
mi
from
Dallas, TX
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
University of Texas Southwestern Medical Center UTSW
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)
mi
from
Salt Lake City, UT
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
University of Virginia Health Systems Univ Virginia
mi
from
Charlottesville, VA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
University of Virginia Health Systems Univ Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
Rockwood Clinic Spokane Location
mi
from
Spokane, WA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
Rockwood Clinic Spokane Location
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5)
mi
from
La Jolla, CA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5)
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated:  11/5/2015
University of California at Los Angeles UCLA (4)
mi
from
Los Angeles, CA
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
Status: Enrolling
Updated: 11/5/2015
University of California at Los Angeles UCLA (4)
mi
from
Los Angeles, CA
Click here to add this to my saved trials